When you look at the sheer numbers, the global Anticoagulation Market is undergoing a massive shift toward "Factor XI Inhibitors." For decades, the primary challenge for physicians has been the "bleeding-clotting" see-saw. In 2026, new clinical data suggests that targeting Factor XI can prevent stroke and venous thromboembolism (VTE) without compromising the body's natural wound-healing ability...